Startups
CTI BioPharma (NASDAQ: CTIC) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. Pacritinib is also being investigated in acute graft versus host disease (GvHD) in an ongoing investigator-sponsored Phase 1/2 study. We are headquartered in Seattle, Washington.
Overview
Location
United States, Washington, Seattle
Employees
201-500
Founded date
1992
Investors 3
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 6, 2022 | Hercules Capital | htgc.com |
| Ignite 500 | ignite500.com |
Mentions in press and media 29
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 20, 2023 | Sobi to present new data at ASH 2023 Annual Meeting | Sobi to present new data at ASH 2023 Annual Meeting Mon, Nov 20, 2023 08:00 CET Report this content Sobi® will present new data at the 65th Annual Meeting of the American Society of Hematology (ASH) in San Diego from the 9th to the 12th of ... |
| May 25, 2023 | Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp. | Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp. Thu, May 25, 2023 13:30 CET Report this content NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTI... |
| May 10, 2023 | Sobi to acquire CTI BioPharma Corp. enhancing Sobi’s position in rare haematology | Sobi to acquire CTI BioPharma Corp. enhancing Sobi’s position in rare haematology Wed, May 10, 2023 07:00 CET Report this content NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO ... |
| May 10, 2023 | Sobi to Acquire CTI BioPharma, for Approx. $1.7 Billion | Swedish Orphan Biovitrum AB (STO: SOBI) (“Sobi”), a global healthcare leader in hematology, immunology and specialty care, is to acquire CTI BioPharma (Nasdaq: CTIC), a Seattle, WA-based commercial biopharmaceutical company focused on the d... |
| Sep 8, 2021 | CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | |
| Aug 26, 2021 | CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | |
| Aug 24, 2021 | CTI BioPharma Announces Appointment of Diane Parks to Its Board of Directors | |
| Jul 26, 2021 | CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | |
| Jul 9, 2021 | CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Show more
Reviews 0
FAQ about CTI BioPharma
When was CTI BioPharma founded?
CTI BioPharma was founded in 1992.
Who has invested in CTI BioPharma?
Parsers VC lists 3 investors of CTI BioPharma, among them Hercules Capital and Ignite 500.
What has the press written about CTI BioPharma?
Parsers VC has collected 29 articles mentioning CTI BioPharma, among them “Sobi to present new data at ASH 2023 Annual Meeting” (Nov 20, 2023) and “Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.” (May 25, 2023).
Is CTI BioPharma still active?
Yes, CTI BioPharma is active; its latest activity on Parsers VC dates from Jun 10, 2024.